|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
NIAGARA Trial Shows Durvalumab Plus Chemotherapy Improves Survival in Muscle-Invasive Bladder Cancer
|
|
Thomas Powles, MBBS, MRCP, MD
|
| Thomas Powles joins Zachary Klaassen to discuss the NIAGARA trial results. The phase III study examines the addition of durvalumab to cisplatin-based chemotherapy in the perioperative setting for muscle-invasive bladder cancer, representing the largest trial in this space with 1,000 patients.
|
|
|
|
|
|
|
|
|
|
|
|
|
5-Year Survival Outcomes in Cisplatin-Ineligible Patients from EV-103
|
|
Jonathan Rosenberg, MD
|
| Alicia Morgans hosts Jonathan Rosenberg to discuss the five-year outcomes from EV-103 Cohort A, examining enfortumab vedotin plus pembrolizumab in cisplatin-ineligible advanced urothelial cancer patients.
|
|
|
|
|
|
|
|
|
|
|
|
|
Phase 2 Trial: Chemotherapy Plus Immunotherapy Facilitates Bladder Sparing in Muscle-Invasive Bladder Cancer
|
|
Matthew Galsky, MD
|
| Ashish Kamat and Matthew Galsky discuss a phase 2 trial on organ sparing for muscle-invasive bladder cancer, published in Nature Medicine.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EDITOR SELECTED CONFERENCE COVERAGE & COMMENTARIES
|
|
|
|
|
| Outcomes of Patients with BCG–unresponsive High-Risk Non–muscle-Invasive Bladder Cancer Who Demonstrated Nonresponse to Pembrolizumab in KEYNOTE-057: A Post Hoc Analysis |
| Roger Li, MD |
| A post hoc analysis of the KEYNOTE-057 trial assessed outcomes for BCG-unresponsive high-risk non–muscle-invasive bladder cancer patients who did not respond to pembrolizumab. Findings suggest that both bladder-sparing therapies and radical cystectomy offer similar oncologic outcomes following pembrolizumab nonresponse, with comparable progression-free survival across groups. The analysis supports the feasibility of a safe treatment window to explore second-line bladder-sparing therapies before considering radical cystectomy, aiding patients and clinicians in treatment planning. |
|
|
|
|
|
| A Randomized Phase 3 Trial of Neoadjuvant Durvalumab plus Chemotherapy Followed by Radical Cystectomy and Adjuvant Durvalumab in Muscle-Invasive Bladder Cancer (NIAGARA) |
| Petros Grivas MD, PhD |
| Petros Grivas reviews the NIAGARA trial, a phase 3 study evaluating neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab for muscle-invasive bladder cancer (MIBC). Results showed benefits in event-free survival (EFS) and overall survival (OS), marking NIAGARA as a potential practice-changing approach in perioperative MIBC treatment. |
|
|
|
|
|
|
|
|
|
|
| Clinical Outcomes in Patients with High-Risk, Post-Cystectomy Muscle-Invasive Bladder Cancer with Persistent ctDNA- Status on Serial Testing: Surveillance Analysis from the IMvigor011 Study
|
| Thomas Powles, MBBS, MRCP, MD
|
| Thomas Powles presents the findings from the IMvigor011 study, which analyzed outcomes in patients with high-risk, post-cystectomy muscle-invasive bladder cancer who showed persistent ctDNA-negative (ctDNA-) status on serial testing. This research focused on evaluating the potential of serial ctDNA monitoring as a prognostic tool for identifying patients with a low risk of recurrence.
|
|
|
|
|
|
| Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314 - Beyond the Abstract
|
| Yi-Tsung Lu, Melissa Plets, Gareth Morrison, Alexander T Cunha, Steven Y Cen, Suhn K Rhie, Kimberly D Siegmund, Siamak Daneshmand, David I Quinn, Joshua J Meeks, Seth P Lerner, Daniel P Petrylak, David McConkey, Thomas W Flaig, Ian M Thompson, Amir Goldkorn
|
| In locally advanced bladder cancer, neoadjuvant chemotherapy offers a modest survival benefit, but it is effective in some patients while adding toxicity and delaying surgery in others. There is a pressing need for new biomarkers that can predict which patients will benefit from this treatment.
|
|
|
|
|
|
| Quantifying Intra-tumoral Molecular Subtype Heterogeneity in MIBC from Histological Slides Using a Deep Learning Approach in the VESPER Trial
|
| Jacqueline Fontugne, MD
|
| The 2024 IBCN annual meeting included a session on treatment response correlates, featuring a presentation by Dr. Jacqueline Fontugne discussing the quantification of intra-tumoral molecular subtype heterogeneity in muscle invasive bladder cancer from histological slides using a deep learning approach in the VESPER trial.
|
|
|
|
|
|
|
|
|
|
|
| Honing the Hunt: A Comprehensive Review of Cell-free Tumor DNA to Predict Neoadjuvant Therapy Efficacy in Bladder Cancer - Beyond the Abstract
|
| Caio Vinícius Suartz, MD
|
| This research provides a comprehensive examination of the role of cell-free DNA (cfDNA) in predicting responses to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer (MIBC). Here, I delve deeper into the methodologies, findings, and implications of this study.
|
|
|
|
|
|
|
|
|
|
|
